🚀 VC round data is live in beta, check it out!
Chemomab Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Chemomab Therapeutics and similar public comparables like Biogened, Cellectar Biosciences, Medicon Hellas, Alligator Bioscience and more.
Chemomab Therapeutics Overview
About Chemomab Therapeutics
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Founded
2011
HQ
Employees
16
Website
Sectors
Financials (FY)
EV
$2M
Chemomab Therapeutics Financials
Chemomab Therapeutics reported last fiscal year revenue of — and negative EBITDA of ($9M).
In the same fiscal year, Chemomab Therapeutics generated ($9M) in EBITDA losses and had net loss of ($9M).
Revenue (LTM)
Chemomab Therapeutics P&L
In the most recent fiscal year, Chemomab Therapeutics reported revenue of — and EBITDA of ($9M).
Chemomab Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($9M) | XXX | XXX | XXX |
| Net Profit | ($10M) | XXX | ($9M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Chemomab Therapeutics Stock Performance
Chemomab Therapeutics has current market cap of $12M, and enterprise value of $2M.
Market Cap Evolution
Chemomab Therapeutics' stock price is $1.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2M | $12M | -1.8% | XXX | XXX | XXX | $-1.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChemomab Therapeutics Valuation Multiples
Chemomab Therapeutics trades at (0.2x) EV/EBITDA.
Chemomab Therapeutics Financial Valuation Multiples
As of April 11, 2026, Chemomab Therapeutics has market cap of $12M and EV of $2M.
Equity research analysts estimate Chemomab Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chemomab Therapeutics has a P/E ratio of (1.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12M | XXX | $12M | XXX | XXX | XXX |
| EV (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.2x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
| P/E | (1.2x) | XXX | (1.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Chemomab Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Chemomab Therapeutics Margins & Growth Rates
Chemomab Therapeutics' revenue in the last fiscal year grew by —.
Chemomab Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.
Chemomab Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (35%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Chemomab Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biogened | XXX | XXX | XXX | XXX | XXX | XXX |
| Cellectar Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Medicon Hellas | XXX | XXX | XXX | XXX | XXX | XXX |
| Alligator Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Wellgistics Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chemomab Therapeutics M&A Activity
Chemomab Therapeutics acquired XXX companies to date.
Last acquisition by Chemomab Therapeutics was on XXXXXXXX, XXXXX. Chemomab Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Chemomab Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChemomab Therapeutics Investment Activity
Chemomab Therapeutics invested in XXX companies to date.
Chemomab Therapeutics made its latest investment on XXXXXXXX, XXXXX. Chemomab Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Chemomab Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Chemomab Therapeutics
| When was Chemomab Therapeutics founded? | Chemomab Therapeutics was founded in 2011. |
| Where is Chemomab Therapeutics headquartered? | Chemomab Therapeutics is headquartered in Israel. |
| How many employees does Chemomab Therapeutics have? | As of today, Chemomab Therapeutics has over 16 employees. |
| Who is the CEO of Chemomab Therapeutics? | Chemomab Therapeutics' CEO is Adi Mor. |
| Is Chemomab Therapeutics publicly listed? | Yes, Chemomab Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Chemomab Therapeutics? | Chemomab Therapeutics trades under CMMB ticker. |
| When did Chemomab Therapeutics go public? | Chemomab Therapeutics went public in 2021. |
| Who are competitors of Chemomab Therapeutics? | Chemomab Therapeutics main competitors are Biogened, Cellectar Biosciences, Medicon Hellas, Alligator Bioscience. |
| What is the current market cap of Chemomab Therapeutics? | Chemomab Therapeutics' current market cap is $12M. |
| Is Chemomab Therapeutics profitable? | No, Chemomab Therapeutics is not profitable. |
| What is the current net income of Chemomab Therapeutics? | Chemomab Therapeutics' last 12 months net income is ($10M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.